Russian Heart Failure Journal 2011year Clinical efficacy of prolonged use of ivabradine in female outpatients

To access this material please log in or register

Register Authorize

Clinical efficacy of prolonged use of ivabradine in female outpatients

Tsareva V. M., Hozyainova N. Y., Agafonov A. N., Romanchenko N. V.

Keywords: arterial hypertension, women, ivabradine, coronary artery disease, remodeling, Holter monitoring, heart rate

DOI: 10.18087/rhfj.2011.1.1434

Background. HR is an independent prognostic factor associated with cardiovascular mortality. Objective. To study the influence of sinus node If -inhibitor ivabradine on structural and functional characteristics of heart, heart rate, ST-depression, corrected QT interval and its dispersion in female outpatients. Materials and methods. This single-center open-label prospective study included 29 women (63.2±5.4 years) with CAD and LV dysfunction (LVEF – 40.5±4.3 %). 66 % of patients had myocardial infarction in anamnesis, 72 % – hypertension. Average heart rate was 79.4±6.1 beats per min. 86 % of patients received regular treatment (β-blockers – 62 % of women). Ivabradine was administered at a dose 5–7.5 mg 2 times a day (average dose – 12.7±2.1 mg / day). At baseline and in 52 weeks of treatment all patients underwent Holter ECG, echocardiography. Results. Long-term therapy with ivabradine is promising in prevention and treatment of heart failure in women with ischemic LV dysfunction.
  1. Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J. 1993;125 (4):1148–1154.
  2. Kannel WB, Kannel C, Puffenbarger RS et al. Heart rate and cardiovascular mortality. The Framingham Study. Am Heart J. 1987;113 (6):1489–1494.
  3. Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986;7 (4):279–288.
  4. Fox K, Steg PG. Elevated heart rate proven to increase coronary events. Cardiovasc J. 2008;19 (5):276–278.
  5. Шальнова С. В., Деев А. Д., Оганов Р. Г. и др. Частота пульса и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Резуль­таты эпидемиологического исследования. Кардиология. 2005;45 (10):45–50.
  6. Borer JS, Fox K, Jaillon P et al. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107 (6):817–823.
  7. Vilaine JP, Bidouard JP, Lesage L et al. Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs. J Cardiovasc Pharmacol. 2003;42 (5):688–696.
  8. Heusch G. Pleiotropic actions of the bradycardic agent ivabradine: cardiovascular protection beyond heart rate reduction. Br J Pharmacol. 2008;55 (7):970–971.
  9. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27 (11):1341–1381.
  10. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008;15 (5):461–473.
  11. Ferrari R, Ford I, Fox K et al. The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction – baseline characteristics of the study population. Cardiology. 2008;110 (4):271–282.
  12. Fox K, Ford I, Steg PG et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet. 2008;372 (9641):817–821.
Tsareva V.M., Hozyainova N.Y., Agafonov A.N. et al. Clinical efficacy of prolonged use of ivabradine in female outpatients. Russian Heart Failure Journal. 2011;12(1):15-17.

To access this material please log in or register

Register Authorize
Ru En